Literature DB >> 22139790

Prevalence of diagnosed adult immune thrombocytopenia in the United Kingdom.

Dimitri Bennett1, M Elizabeth Hodgson, Amit Shukla, John W Logie.   

Abstract

INTRODUCTION: Data regarding the prevalence of immune thrombocytopenia (ITP) is limited, and is derived from North American population-based analyses. Therefore, the authors conducted the first study outside the United States (US) using the United Kingdom (UK) General Practice Research Database (GPRD) to estimate the adult prevalence of ITP in the UK.
METHODS: This study estimated the diagnosed prevalence of ITP in the adult population in UK using the GPRD from January 1, 1992 to December 31, 2009.
RESULTS: The unadjusted, overall 18-year period prevalence was 50.29/100,000 (95% CI: 48.51, 52.06). The age- and gender-adjusted, overall 18-year period prevalence was 50.00/100,000 (95% CI: 49.20, 50.90). ITP prevalence was lower in adults aged 18-49 years of age (30.09/100,000, 95% CI: 28.27, 31.90) than in older adults aged 50-64 years of age (58.22/100,000, 95% CI: 53.88, 62.57) or ≥65 years of age (93.80/100,000, 95% CI: 88.76, 98.85). Prevalence was higher among females (59.32/100,000, 95% CI: 56.63, 62.01) than in males (40.66/100,000, 95% CI: 38.36, 42.96). Prevalence in the GPRD increased over time (1992 [16.33/100,000, 95% CI: 13.70, 19.00], 2000 [36.93/100,000, 95% CI: 34.50, 39.30], and 2009 [58.49/100,000, 95% CI: 55.80, 61.20]).
CONCLUSION: This new analysis of general practice in the UK provides robust prevalence estimates of diagnosed ITP among adults in Europe. ITP prevalence is higher in women and increases with age and over time.

Entities:  

Mesh:

Year:  2011        PMID: 22139790     DOI: 10.1007/s12325-011-0084-3

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  10 in total

1.  Immune thrombocytopenia: getting back to basics.

Authors:  Donald M Arnold
Journal:  Am J Hematol       Date:  2012-07-05       Impact factor: 10.047

2.  Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome.

Authors:  Lamiae Grimaldi-Bensouda; Clémentine Nordon; Marc Michel; Jean-François Viallard; Daniel Adoue; Nadine Magy-Bertrand; Jean-Marc Durand; Philippe Quittet; Olivier Fain; Bernard Bonnotte; Anne-Sophie Morin; Nathalie Morel; Nathalie Costedoat-Chalumeau; Brigitte Pan-Petesch; Mehdi Khellaf; Antoinette Perlat; Karim Sacre; François Lefrere; Lucien Abenhaim; Bertrand Godeau
Journal:  Haematologica       Date:  2016-05-26       Impact factor: 9.941

Review 3.  The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS).

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

4.  Association of Thrombocytopenia, Revascularization, and In-Hospital Outcomes in Patients with Acute Myocardial Infarction.

Authors:  Gregory D Rubinfeld; Nathaniel R Smilowitz; Jeffrey S Berger; Jonathan D Newman
Journal:  Am J Med       Date:  2019-04-27       Impact factor: 4.965

5.  Prevalence of primary immune thrombocytopenia in Oklahoma.

Authors:  Deirdra R Terrell; Laura A Beebe; Barbara R Neas; Sara K Vesely; Jodi B Segal; James N George
Journal:  Am J Hematol       Date:  2012-06-05       Impact factor: 10.047

6.  Contributions of T lymphocyte abnormalities to therapeutic outcomes in newly diagnosed patients with immune thrombocytopenia.

Authors:  Zhenhua Zhao; Lei Yang; Guohua Yang; Yun Zhuang; Xifeng Qian; Xin Zhou; Dajiang Xiao; Yunfeng Shen
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

7.  Increased Frequency of Immune Thrombocytopenic Purpura in Coeliac Disease and Vice Versa: A Prospective Observational Study.

Authors:  Stefano Bibbò; Claudio Fozza; Giovanni Mario Pes; Rodrigo Rojas; Roberto Manetti; Maria Pina Dore
Journal:  Gastroenterol Res Pract       Date:  2018-04-23       Impact factor: 2.260

8.  Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.

Authors:  Indraraj Umesh Doobaree; Adrian Newland; Vickie McDonald; Raghava Nandigam; Lesley Mensah; Sandrine Leroy; Anouchka Seesaghur; Hitan Patel; Sally Wetten; Drew Provan
Journal:  Eur J Haematol       Date:  2019-03-07       Impact factor: 2.997

9.  Immune thrombocytopenic purpura increased risk of subsequent pancreatitis: A Nationwide population cohort study.

Authors:  Shih-Chi Wu; Sheng-Fung Lin; Chu-Wen Fang; I-Ju Tsai; Wen-Chi Yang
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

10.  Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.

Authors:  Alicia Rovó; Nathan Cantoni; Kaveh Samii; Axel Rüfer; Giedre Koenen; Sandra Ivic; Davide Cavanna; Rudolf Benz
Journal:  PLoS One       Date:  2022-04-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.